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Paclitaxel is a common chemotherapeutic agent that is effective against various cancers. The poor aqueous solubility
of paclitaxel necessitates a large percentage of Cremophor EL:ethanol (USP) in its commercial formulation which leads
to hypersensitivity reactions in patients. We evaluate the use of a crystalline nanosuspension versus the USP
formulation to deliver paclitaxel to tumor-bearing xenograft mice. Anti-tumor efficacy was assessed following
intravenous administration of three 20 mg/kg doses of paclitaxel. Paclitaxel pharmacokinetics and tissue distribution
were evaluated, and differences were observed between the two formulations. Plasma clearance and tissue to plasma
ratio of mice that were dosed with the nanosuspension are approximately 33- and 11-fold higher compared to those
of mice that were given the USP formulation. Despite a higher tumor to plasma ratio for the nanosuspension
treatment group, absolute paclitaxel tumor exposure was higher for the USP group. Accordingly, a higher anti-tumor
effect was observed in the xenograft mice that were dosed with the USP formulation (90% versus 42% tumor growth
inhibition). This reduction in activity of nanoparticle formulation appeared to result from a slower than anticipated
dissolution in vivo. This study illustrates a need for careful consideration of both dose and systemic solubility prior
utilizing nanosuspension as a mode of intravenous delivery.
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Paclitaxel is a chemotherapeutic agent used for the treat-
ment of cancers. It acts by interfering with a cell's
microtubule function by stabilizing microtubule forma-
tion, thereby inhibiting mitosis and normal cell division.
Paclitaxel shows broad anti-tumor activity and is used to
treat a wide variety of cancers such as ovarian, breast,
non-small cell lung, head and neck cancer, and advanced
forms of Kaposi's sarcoma [1-4]. Despite its broad use as
a chemotherapeutic, the delivery of paclitaxel is challen-
ging. Paclitaxel is a well-known BCS class IV drug with
poor solubility and poor permeability which serves to
limit its oral uptake. Also, paclitaxel is a substrate of the* Correspondence: chiang.pochang@gene.com; wong.harvey@gene.com
1Department of Pharmaceutics, Genentech, Inc., 1 DNA Way, South San
Francisco, CA 94080, USA
3Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1
DNA Way, South San Francisco, CA 94080, USA
Full list of author information is available at the end of the article
© 2014 Chiang et al.; licensee Springer. This is
Attribution License (http://creativecommons.or
in any medium, provided the original work is pmembrane-bound drug efflux pump P-glycoprotein
(P-gp), which can prevent oral absorption or uptake by
mediating direct excretion of the drug into the intestinal
lumen [1,5]. Finally, significant pre-systemic first-pass
metabolism in the liver by the cytochrome P450 en-
zymes further reduces the oral bioavailability of pacli-
taxel [6-8].
As a result of the described challenges to oral delivery,
the current route of paclitaxel administration is via the
intravenous (IV) route. Due to its poor solubility, pacli-
taxel is dissolved in organic mix of Cremophor EL (BASF,
Ludwigshafen, Germany):ethanol (1:1 v/v) for intravenous
delivery. Cremophor EL is a polyoxyethylated castor oil,
and its inclusion in the delivery vehicle has resulted in se-
vere hypersensitivity reactions occurring after IV adminis-
tration [9-15]. Anti-allergic pre-medication treatment
with corticosteroids and antihistamines has been used to
reduce the incidence of adverse reactions associated withan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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reactions still occur in 5% to 30% of patients [4]. The de-
scribed liability highlights the need for a new formulation
vehicle. Tween 80- and Tween 80/ethanol-based formula-
tions with subsequent dilution using aqueous media have
been tested for paclitaxel. In both cases, dilution with
aqueous media resulted in precipitation of paclitaxel
which was a major concern [16-19]. Liposome-based for-
mulations have also been tested and have shown promise
[20-22]. However, drawbacks for liposome formulations
include rapid degradation due to the reticuloendothelial
system (RES), an inability to achieve sustained drug deliv-
ery over a prolonged period of time [23], and low drug
load which often limits their application. Thus, there is
still a need to explore alternate formulations for paclitaxel
and poorly soluble compounds in general.
Recently, the use of nano- and microparticle drug de-
livery in the pharmaceutical industry has been reported.
This formulation technology has been applied to a var-
iety of dosing routes including the oral, intraperitoneal
(IP), intramuscular (IM), inhalation, intratracheal (IT),
intranasal (IN), and subcutaneous (SC) dosing routes, or
to enable direct target delivery [24-28]. The main advan-
tage of using nano- or microparticle delivery systems is
that the small particle size creates an increased surface
area which acts to enhance the overall dissolution rate,
thereby improving the bioavailability of extravascular
dosing routes without the use of solvents. The described
advantage of an improved dissolution rate can also be
applied to the IV route [28-34]. The use of nanoparticles
for IV formulations has recently drawn much attention
[28-34]. However, there is a need for more in vivo inves-
tigations evaluating intravenous delivery with nanoparticle
formulations. The impact of intravenous nanosuspension
delivery on pharmacokinetics, tissue/organ distribution,
and pharmacodynamics/efficacy are not fully understood.
The objective of our current study is to investigate the ef-
fect of intravenous nanosuspension delivery of paclitaxel
to a xenograft mouse tumor model compared to the
standard Cremophor EL:ethanol formulation. In particu-
lar, comparisons of pharmacokinetics, organ distribution,
and anti-tumor effect were evaluated for both formula-
tions following intravenous administration. We observe
differences in paclitaxel pharmacokinetics, tissue distribu-
tion, and most importantly anti-tumor effect due to nano-
suspension delivery.
Methods
High-performance liquid chromatography (HPLC)-
grade acetonitrile was obtained from Burdick & Jackson
(Muskegon, MI, USA), reagent-grade formic acid was
obtained from EM Science (Gibbstown, NJ, USA), and
paclitaxel bulk drug was purchased from Sigma-Aldrich
(St. Louis, MO, USA). Commercially available paclitaxel(Cremophor EL:ethanol) was manufactured by Bristol-
Myers Squibb (New York, NY, USA). Other chemicals
were either made in-house (Genentech, Inc., South San
Francisco, CA, USA) or purchased from Sigma-Aldrich.
The water purification system used was a Millipore
Milli-Q system (Billerica, MA, USA).
Powder X-ray diffraction pattern and particle size
determination
Powder X-ray diffraction (PXRD) patterns were recorded
at room temperature with a Rigaku (The Woodlands,
TX, USA) MiniFlex II desktop X-ray powder diffractom-
eter. Radiation of Cu Kα at 30 kV and −15 mA was used
with 2θ increment rate of 3°/min. The scans were run
over a range of 2° to 40° 2θ with a step size of 0.02° and
a step time of 2 s. Powder samples were placed on a flat
silicon zero background sample holder.
The particle size distribution of the nanosuspension
was measured by using a Nanotrac (Montgomeryville,
PA, USA) instrument. Triplicates were measured for each
sample, and the average was used for the final particle
size distribution. The particle size distribution was calcu-
lated based on the general purpose (normal sensitivity)
analysis model and the following refractive indices (RIs):
particle RI, 1.58; absorption, 1.0; and dispersant RI, 1.38.
Formulation preparation for paclitaxel IV crystalline
nanosuspension and stability evaluation
A bench scale wet milling method was developed for
particle size reduction and has been previously described
[33]. Briefly, a paclitaxel stock nanosuspension formula-
tion (20 mg/mL) was prepared by mixing paclitaxel with
an appropriate amount of glass beads and vehicle con-
taining 0.1% (w/w) Cremophor EL in phosphate saline
(pH 7.4) in a scintillation vial. The mixture was stirred
at 1,200 rpm for a period of 24 h with occasional shak-
ing. The resulting stock formulation was diluted to the
target concentration with vehicle and then harvested.
Paclitaxel concentrations were verified by a HPLC assay.
Analysis of milled paclitaxel particles was performed
using a Nanotrac (Montgomeryville, PA, USA) instru-
ment. An assessment of form change in pre- and post-
milling samples was performed using PXRD.
The rate of dissolution of paclitaxel in nanosuspension
is expected to be higher compared to regular suspension
due to the reduction of particle size. The Noyes and
Whitney equation (Equation 1) was used in order to as-
sess the impact of particle size reduction on dissolution
rate and is described as follows:
dC=dt ¼ D S Cs − Ct tð Þð Þ=Vhd ð1Þ
where dC/dt is the dissolution rate, D is the solute diffu-
sion coefficient, V is the volume of the dissolution
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surface area of the solute, Cs is the saturation solubility
of the solute, and Ct(t) is the bulk solute concentration.
The stability of the crystalline nanosuspension was mon-
itored for a period of 3 weeks for particle size, PXRD,
and chemical stability (by HPLC). Paclitaxel plasma
solubility was determined by adding excess amount of
paclitaxel bulk drug into 0.5 mL of rodent plasma (ob-
tained in-house) which was allowed to equilibrate at
37°C on a rotary shaker for a period of 24 h. Excess
drug was then removed by centrifugation which was
followed by protein precipitation, and the concentra-
tion was measured by HPLC with an external standard.Efficacy and pharmacokinetic study in xenograft mice
Briefly, 2.5 million Calu-3 non-small cell lung cancer cells
were resuspended in Hank's balanced salt solution and
implanted intradermally into the hind flank of female
SCID-bg mice (Charles River Laboratories, Hollister, CA,
USA). When tumor volumes reached approximately 150
to 300 mm3, mice were randomly assigned to three treat-
ment groups. Treatment groups were administered one
intravenous dose every 4 days of either vehicle (Cremo-
phor EL:ethanol 1:1, saline; n = 10), paclitaxel formulated
in Cremophor vehicle (n = 15), or paclitaxel formulated in
nanosuspension (n = 15). A total of three doses were
given during the course of the study. The paclitaxel dose
was selected in an attempt to match as best possible clin-
ically relevant exposures and at the same time provide ro-
bust anti-tumor efficacy when delivered with the
commercial formulation (Cremophor EL:ethanol 1:1).
Tumor volumes were measured in two dimensions
(length and width) using Ultra Cal-IV calipers (Model 54-
10-111, Fred V. Fowler Company, Inc., Newton, MA,
USA). The following formula was used with Excel v11.2
(Microsoft Corporation, Redmond, WA, USA) to calcu-
late tumor volume (TV): TV (mm3) = (length × width2) ×
0.5. Tumor sizes and body weights were recorded twice
weekly, and the mice were regularly observed over the
course of the study. Mice were euthanized if their tumor
volume exceeded 2,000 mm3 or if their body weight
dropped by more than 20% of the starting weight. At end
of the study, mice in both paclitaxel groups were given a
final dose of paclitaxel, and blood (collected by terminal
cardiac puncture and plasma-harvested) and tissues (liver,
spleen, and tumor) were collected at various time
points (10 min, 30 min, 2 h, 4 h, and 8 h post-dose).
Three mice were taken down at each time point, and
biological samples were frozen at −70°C until sampling.
Paclitaxel concentrations in plasma and tissues were
measured by a liquid chromatography tandem mass
spectrometry (LC/MS/MS) assay. The study was con-
ducted in accordance with the institutional guidelinesfor humane treatment of animals and was approved by
the IACUC of Genentech.LC/MS/MS assay for the determination of paclitaxel
Concentrations of paclitaxel in mouse plasma, tumor,
liver, and spleen were determined by a LC/MS/MS assay.
Tumor, liver, and spleen tissue samples were diluted 4-
fold with water and homogenized by using a FastPrep-24
bead beater (MP Biomedicals, Solon, OH, USA). The
plasma and tissue homogenate samples were prepared for
analysis by placing a 25-μL aliquot into a 96-well plate
followed by the addition of 5 μL of internal standard (do-
cetaxel, 2 μg/mL in 50:50, v/v, DMSO:water) and 200 μL
acetonitrile. The samples were vortexed and centrifuged
at 1,600 g for 15 min at room temperature, 50 μL of the
supernatant was diluted with 150 μL of water, and 5 μL
of the solution was injected onto a Kinetex XB C-18
(30 × 2.1 mm, 2.6 μm) analytical column (Phenomenex,
Torrance, CA, USA).
An Agilent 1290 Infinity HPLC system (Agilent, Santa
Clara, CA, USA) was equipped with a controller, two
pumps, a column compartment, and a degasser. The
column was maintained at 40°C by the column compart-
ment. This system was coupled to an API 5500 Qtrap
mass spectrometer (AB Sciex, Foster City, CA, USA)
equipped with a turbo-electrospray interface in positive
ionization mode. The aqueous mobile phase was water
with 0.1% formic acid (A), and the organic mobile phase
was acetonitrile with 0.1% formic acid (B). The gradient
was as follows: starting at 15% B and increased to 95% B
for 0.6 min, maintained at 95% B for 0.1 min, then de-
creased to 15% B within 0.1 min. The total flow rate was
1.4 mL/min. Data was collected using multiple reaction
monitoring (MRM) with transitions m/z 854.4→ 104.9
for paclitaxel and m/z 808.5→ 527.2 for docetaxel (in-
ternal standard). The calibration curve, which ranged
from 0.03 to 24 μM for paclitaxel, was fitted to a 1/x
weighted quadratic regression model. This calibration
curve was used to quantitate paclitaxel concentration
levels in the plasma, tumor, liver, and spleen samples.Data analysis
Pharmacokinetic parameters were estimated by non-
compartmental methods as described by Gibaldi and
Perrier [35] using WinNonlin version 3.2 (Pharsight
Corporation, Mountain View, CA, USA). Tissue to
plasma ratios were determined by dividing the AUC0-8
(area under the concentration-time profile from 0 to
8 h) of the tissue of interest by the AUC0-8 of plasma.
The percent tumor growth inhibition (%TGI) was cal-
culated on the last day of the study (day 17) using the
following formula as previously described [36]:
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TVvehicle is the tumor volume for the vehicle-treated
animals on day 17, TVinitial is the initial tumor volume at
the start of the treatment, and TVtreatment is the tumor
volume of the treatment groups on day 17. Normalized
efficacy was determined with respect to plasma and
tumor exposures for both Cremophor EL:ethanol and
nanosuspension delivery. Normalized efficacy was deter-
mined by dividing TGI by either plasma or tumor
AUC0-8.
Results
Formulation preparation for paclitaxel IV crystalline
nanosuspension and stability evaluation
A theoretical calculation was performed to estimate the
target particle size at which a nanoparticle should rapidly
dissolve in the bloodstream (i.e., < 10 s under non-stirred
condition) upon intravenous administration. In order to
estimate the dissolution rate of the nanoparticles in blood
upon IV administration, the Stokes-Einstein equation
[33,34] was used to estimate the diffusion coefficient (for
free diffusion assuming a spherical molecule):
D ¼ kT
6πrη
where k is the Boltzmann constant (1.38 × 10−23 J/K), η
is the solvent viscosity (kg/ms; for blood = 0.035 kg/ms),
T is the temperature (K; 37°C), and r is the solute mol-
ecule radius (cm).
This equation can be extended to relate the diffusion
coefficient to the molecular weight and density of the
molecule of interest:









where N is Avogadro's number, V is the molar volume
of the solute, r is the hydrodynamic radius, which con-
siders the solvent bound to the solute, and ρ is the dens-
ity of the solute.
The resulting equation is as follows:
D ¼ kT
6πη 3 MWð Þ4πN ρ
h i1
3=
Using the MW for paclitaxel (MW= 853.9), the diffu-
sion coefficient (D) was calculated to be 9.5 × 10−7 cm2/s.
An estimate of the particle radius needed to achieve a dis-
solution time of <10 s under non-stirred sink conditionwas determined using the Hixson-Crowell cube root law
[33,34]:
Γ ¼ ρ ro2=2DCs
where Γ is the estimate time for complete dissolution, ρ
is the density of the solution, ro is the radius of the par-
ticle, D is the diffusion coefficient, Cs is the solubility in
plasma at 37°C (40 μg/mL).
Based on the relationship described above, the calcu-
lated target mean radius for the paclitaxel nanoparticles
was calculated to be 0.6 μm under sink conditions. The
paclitaxel nanosuspension was characterized in order to
ensure its proper preparation. D50 and D90 of paclitaxel
particles in the IV formulation were determined to be 0.4
and 0.7 μm, respectively (Figure 1). A D50 of 0.4 μm was
within the mean target radius of 0.6 μm. PXRD
characterization of the solid form of the nanomaterial in-
dicated no significant change in crystal form from the
milling process (Figure 2). The paclitaxel crystalline nano-
suspension formulation was stable at room temperature
with no significant changes in PXRD, particle size, and
chemical stability over a period of 3 weeks.
Using a previously published theoretical calculation
[30,33,34], measured paclitaxel solubility in plasma (40 ±
2 μg/mL at 37°C), and the D50 listed above, the estimated
dissolution time of an average paclitaxel particle in the
nanosuspension was estimated to be less than 5 s. The ac-
tual in vivo dissolution time should theoretically be much
more rapid since turbulent blood flow in the vein should
serve to both reduce the diffusion boundary thickness
and rapidly disperse the injection formulation minimizing
local concentration effects [33,34].
Plasma and tissue pharmacokinetics in tumor-bearing
xenograft mice
Paclitaxel plasma, tumor, spleen, and liver concentration-
time profiles following intravenous administration at
20 mg/kg using the Cremophor EL:ethanol and nanosus-
pension formulations are presented in Figures 3 and 4, re-
spectively. The plasma clearance of paclitaxel after
intravenous dosing was substantially higher with nanosus-
pension (158.3 mL/min/kg) delivery compared to the
standard Cremophor EL:ethanol formulation (4.9 mL/
min/kg). Accordingly, plasma AUC0-8 was approximately
40-fold less with nanosuspension delivery (Table 1).
Tumor concentrations (Figures 3 and 4) and exposures
(Table 1) were higher for Cremophor EL:ethanol delivery
with AUC0-8 being approximately 3-fold higher compared
to nanosuspension delivery. In contrast, paclitaxel liver
concentrations (Figures 3 and 4) and exposures (Table 1)
were higher for nanosuspension delivery with AUC0-8 be-
ing approximately 6-fold higher than that observed for
Figure 1 Particle size characterization of paclitaxel nanosuspension.
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was comparable for the two formulations (Table 1).
Paclitaxel tissue to plasma ratios were determined in
order to assess formulation-dependent differences in tis-
sue distribution in tumor, spleen, and liver (Table 2). De-
livery with nanosuspension resulted in higher tissue to
plasma ratios for all three organs investigated (Figure 5,
Table 2). In particular, the liver to plasma ratio wasFigure 2 PXRD of paclitaxel post-milling (top) and API (bottom).exceptionally high being approximately 225-fold higher
with nanosuspension delivery.
Anti-tumor efficacy of paclitaxel
In order to compare the relative efficacy of Cremophor
EL:ethanol versus nanosuspension delivery, percent
tumor growth inhibition was determined at the end
of the study. Delivery of paclitaxel with the standard
Figure 3 Paclitaxel concentration-time profile in plasma, tumor, liver, and spleen following intravenous administration using
Cremophor EL:ethanol formulation.
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(Figure 6). The use of nanosuspension for intravenous
delivery resulted in considerably less efficacy with TGI
being 42%.
In order to normalize the anti-tumor efficacy with dif-
ferences in paclitaxel exposure observed with the two
formulations, TGI was normalized with respect to the
plasma and the site of action (i.e., tumor). Figure 7
shows normalized efficacy with respect to plasma and
tumor exposures for both formulations. The normalizedFigure 4 Paclitaxel concentration-time profile in plasma, tumor, liver,
nanosuspension formulation.efficacy with respect to plasma was considerably higher
for nanosuspension delivery being approximately 20-fold
higher compared to delivery with Cremophor EL:etha-
nol. However, when efficacy was normalized with respect
to tumor which is the site of action, there was little dif-
ference in normalized efficacy between the two formula-
tions (Figure 7).
Body weight changes were also monitored in the xeno-
graft mouse efficacy study in order to give a crude as-
sessment of formulation tolerability (Figure 8). Thereand spleen following intravenous administration using
Table 1 Exposure (mean value) of paclitaxel in plasma,
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changes when comparing the three treatment groups of
mice.
Discussion
Poorly soluble compounds are an increasing problem in
the pharmaceutical industry. The oral and intravenous
delivery of an increasing number of poorly soluble com-
pounds for in vivo evaluation is a growing challenge for
formulation scientists. For the oral delivery, particle size
reduction of solid drug substance offers a means to in-
crease the dissolution rate and improve oral bioavailabil-
ity of poorly soluble compounds. As a result, the use of
nanoparticles has been adapted as a formulation ap-
proach to improve the oral delivery of poorly soluble
compounds [24,27]. Similarly, delivery by the intraven-
ous route can also benefit from the use of nanoparticles
since nanoparticle formulations offer the advantage of
reducing the organic solvent content often required for
poorly soluble compounds. The small particle size
afforded by the use of nanoparticles should enable a
rapid, almost instantaneous dissolution of solid particles
following intravenous administration due to a high dis-
solution rate with blood acting as the dissolution media.
However, there are particle size requirements for intra-
venous dosing since the completion of the dissolution
process must be instantaneous due to potential risks
such as phlebitis and undesired organ accumulation that
may occur upon injection [34].
Paclitaxel is an extensively used chemotherapeutic
agent that suffers from very poor solubility. As such, theTable 2 Tissue to plasma exposure ratio of paclitaxel for
tumor, liver, and spleen following intravenous
administration




Tumor AUC0-8/plasma AUC0-8 0.7 8.3
Liver AUC0-8/plasma AUC0-8 3.6 810.0
Spleen AUC0-8/plasma AUC0-8 1.1 16.8
AUC0-8, area under the concentration-time profile from 0 to 8 h.commercial intravenous formulation of paclitaxel requires
the inclusion of Cremophor EL in order to keep it solubi-
lized. The use of Cremophor EL in the intravenous pacli-
taxel formulation has introduced a number of unique
undesirable features including non-linear pharmacokinet-
ics [37] and more importantly hypersensitivity reactions
which require anti-allergic pre-medication with corticoste-
roids and antihistamines [4]. Due to these undesirable
properties, there is a need to explore alternate formula-
tions. We had previously evaluated the use of nanosuspen-
sion to enable intravenous delivery of ten poorly soluble
compounds in a cassette dosing format [34]. In this intra-
venous cassette study, no changes in pharmacokinetics
were observed with nanosuspension delivery compared to
the use of a solution formulation with high organic con-
tent. In contrast, our current work with paclitaxel nano-
suspension delivery shows substantial alterations in the
pharmacokinetic properties of paclitaxel compared with
the standard Cremophor EL formulation (Figures 3 and 4).
Plasma clearance was substantially higher (approximately
30-fold) with nanosuspension delivery. Since paclitaxel
was given intravenously, alterations in plasma pharmaco-
kinetics are attributed entirely to alterations in paclitaxel
distribution and/or systemic elimination. Distribution was
clearly different with higher tissue to plasma ratios in the
spleen, liver, and tumor following nanosuspension delivery
(Figure 5, Table 2). In particular, a high concentration of
paclitaxel was present in the liver. This high sustained
concentration of paclitaxel in the liver may result in an
overestimation of plasma clearance since plasma concen-
trations drop rapidly yet drug was not really eliminated
from the body, but rather trapped in the liver. An explan-
ation for the high concentrations of drug in tissue may be
that the nanoparticles in the nanosuspension may be dis-
solving slower than anticipated in vivo. Our theoretical es-
timation of the required particle size for instantaneous
dissolution was based on assumed sink conditions. We
did not observe alterations in pharmacokinetics in our
previous cassette doing study [34] with intravenous ad-
ministration of ten poorly soluble compounds. However,
in our previous study, low doses (0.5 mg/kg) of each com-
pound were administered, and therefore, the assumption
of sink conditions in vivo was more likely. Our current
study utilizes a 40-fold higher intravenous dose of pac-
litaxel (20 mg/kg). At this dose, it is conceivable that
non-sink conditions likely occurred in vivo since plasma
concentrations that were achieved using the commercial
formulation (see Figure 3) clearly exceed the plasma
solubility of paclitaxel (i.e., 40 μg/mL). The occurrence
of non-sink dissolution conditions following intraven-
ous administration would result in a slower dissolution
rate that would not be considered ‘instantaneous.’ Our
data are consistent with slowly dissolving nanoparticles
being taken up into organs by phagocytic cells of the
Figure 5 Log tissue to plasma ratios for tumor, liver, and spleen following intravenous delivery to mice.
Chiang et al. Nanoscale Research Letters 2014, 9:156 Page 8 of 10
http://www.nanoscalereslett.com/content/9/1/156mononuclear phagocyte system that are abundant in
tissues such as the liver and spleen [38,39]. One pos-
sible way to overcome the above issue is to use infusion
instead of bolus injection (upon fully determining the
PK/PD) to allow better dissolution of the nanoparticles,
where recently, a successful use of nanoparticles to de-
liver drugs to high plasma concentration was reported
[32]. An additional factor that may contribute to the
observed difference in pharmacokinetics is that there
are known non-linearities in pharmacokinetics caused
by Cremophor EL impacting both paclitaxel distribu-
tion and elimination [40]. Since our nanosuspension
formulation contains only a very small percentage (0.1%)
of Cremophor EL compared to the standard commercial
formulation, less non-linearity is expected with nanosus-
pension delivery.
Recently, a paclitaxel nanosuspension formulation was
evaluated in a manuscript describing a pharmacokinetic
study in rats and a tissue distribution study in mice [41].Figure 6 Plots of mean tumor volume versus time in xenograft
mice for intravenous paclitaxel.Similar alterations in paclitaxel plasma clearance was ob-
served following intravenous administration to rats but
were of a lesser magnitude. In the rat study, plasma
clearance was approximately 4-fold higher with nanosus-
pension delivery versus the 30-fold difference that we
observed in our study. In the same manuscript, an evalu-
ation of formulation-dependent changes in tissue distri-
bution in mice was also performed. Higher tissue
accumulation was reported for the liver and spleen in
mice. However, it is difficult to compare results directly
with our current study since plasma was not collected,
and therefore, tissue to plasma ratios were not reported.
Finally, non-tumor-bearing animals were used in the re-
ported study, so there were no comparisons of tumor
disposition and anti-tumor activity.
To date, to our knowledge, there have been little to
no comparisons of pre-clinical anti-tumor efficacy using
nanosuspension formulation to deliver anti-cancer agents
to subcutaneous tumor models. In particular, investiga-
tions on the use of nanosuspension formulation for pacli-
taxel delivery have been limited to the pharmacokinetic/
tissue distribution study that was discussed above [41].Figure 7 Normalized efficacy based on plasma and tumor
concentrations following delivery of paclitaxel to
xenograft mice.
Figure 8 Mean percent body weight change in xenograft mice
given intravenous paclitaxel.
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shows that intravenous delivery of a 20 mg/kg paclitaxel
dose using nanosuspension resulted in reduced efficacy
compared to the standard Cremophor EL:ethanol formu-
lation (Figure 6). Since the plasma and tumor disposition
were altered with nanosuspension delivery, anti-tumor
efficacy normalized with respect to plasma and tumor
exposures was calculated. The calculated measure of
normalized efficacy (i.e., TGI/AUC0-8 ratio) provides an
assessment of efficacy relative to relevant in vivo concen-
trations such that the two formulations can be properly
compared. The TGI/AUC0-8 ratios normalized relative
to plasma exposure were much higher (approximately
16-fold) for nanosuspension delivery compared to the
standard formulation (Figure 7). However, the TGI/AUC0-
8 ratios normalized relative to tumor exposure were
comparable. This observation suggested that the large dif-
ference in the TGI/AUC0-8 ratios normalized relative to
plasma exposure was a result of a higher degree of ac-
cumulation in the tumor occurring with nanosuspension
delivery. Once in the tumor, paclitaxel's anti-tumor effect
was similar and not dependent on the formulation.
Despite having a larger tumor to plasma ratio (Table 2),
nanosuspension delivery resulted in less anti-tumor efficacy
(Figure 6). This occurred because the absolute amount of
paclitaxel getting into the tumor was much less due to
much lower plasma exposures following nanosuspen-
sion delivery (Table 1). Finally, based on the mice body
weights, the tolerability of the nanosuspension formula-
tion was acceptable.
Conclusions
The delivery of poorly soluble drugs using nanoparticles
has received much interest recently for both the oral
and intravenous routes of administration. However,
much of the published literature evaluates the effect ofnanoparticle formulations in pharmacokinetic studies.
Thus, there is a need to examine the impact of nanopar-
ticle delivery in pre-clinical efficacy models. Our current
work compares both pharmacokinetics and anti-tumor
efficacy for paclitaxel delivered using a standard com-
mercial formulation and a nanosuspension. We found
that nanosuspension delivery reduced paclitaxel's anti-
tumor efficacy. This, to our best knowledge, was never
been investigated before. The paclitaxel dose used in our
study was chosen in an attempt to match clinically
relevant exposures and resulted in robust efficacy in the
xenograft tumor-bearing mice when delivered with
the commercial formulation. Based on our findings, the
reduced anti-tumor activity associated with nanosuspen-
sion delivery appeared to be a result of non-sink dissol-
ution conditions present at the paclitaxel dose used in
our study. Finally, the current case study illustrates a
need for careful consideration of both compound dose
and systemic solubility prior to utilizing nanosuspension
as a mode of intravenous delivery.
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